Abstract
Progress in understanding carcinogenesis has shown cancer to be a disease caused by gene abnormalities, and a variety of oncogenes and tumor suppressor genes have thus been identified. Advances in molecular biology have given us new tools for diagnosing, staging and predicting the outcome for cancer patients and gene therapy could therefore potentially revolutionize the treatment of gastrointestinal (GI) tract cancer. Progress has been made in several approaches related to genetic modification: (1) antisense oncogene and the restoration of tumor suppresor gene therapy; (2) suicide gene therapy; and (3) cancer immunotherapy. In situ in vivo gene transfer is a practical method of gene therapy for GI tract cancer. Although many hurdles need to be overcome to achieve effective gene transfer and targeting, our early results of in situ in vivo suicide gene therapy for canine gastric cancer are promising. The era of combined treatment consisting of surgery and molecular surgery for GI tract cancer is thus considered to soon be possible.
References
Anderson WF (1992) Human gene therapy. Science 256:808–813
Shimada T (1996) Current status and future prospects of human gene therapy. Acta Paediat Jap 38:176–181
Mastrangelo M, Berd D, Nathan FE, Lattime EC (1996) Gene therapy for human cancer: an essay for clinicians. Semin Oncol 23:4–21
Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199
Morsy MA, Mitani K, Clemens P, Caskey T (1993) Progress toward human gene therapy JAMA 270:2338–2345
Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ (1996) In situ use of suicide genes for cancer therapy. Semin Oncol 23:31–45
Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, Sorrentino B, Velu T (1995) Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 2:291–297
Miller AD (1992) Human gene therapy comes of age. Nature 357:455–460
Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, Takahashi T (1995) The anti-proliferative effect of proliferating cell nuclear antigen-specific antisense oligonucleotides on human gastric cancer cell lines. Surg Today 25:184–186
Bold RJ, Warren RE, Ishizuka J, Cho-Chung YS, Townsend CMJr, Thompson JC (1994) Experimental gene therapy of human colon cancer, Surgery 116:189–196
Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455
Fujiwara T, Ogawa N, Kagawa S, Nishizaki M, Tanaka N, Zhang W-W, Roth JA (1996) A novel combination therapy for human cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. In: E. Tahara, K. Sugimachi, T. Oohara (eds) Recent advances in gastroenterological carcinogenesis I. Monduzzi Editore, Bologna, pp 1207–1211
Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K-H, Ishitobi M, Omata M (1996) Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 56:1341–1345
Bland KI (1997) Advances in molecular genetics. Am J Surg 173:42–43
Lairmore TC, Norton JA (1997) Advances in molecular genetics. Am J Surg 173:37–41
Fearson ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767
Correa P, Shiao YH (1994) Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54:1941s-1943s
Tahara E (1993) Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 119:265–272
Pollock R (1997) What's new in surgical oncology. J Am Coll Surg 184:157–163
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Onda, M., Matsukura, N. Gene therapy for gastrointestinal tract cancer: Prospects for combination treatment consisting of surgery and molecular surgery. Surg Today 27, 1099–1102 (1997). https://doi.org/10.1007/BF02385675
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02385675